{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:43:54Z","timestamp":1760913834027,"version":"build-2065373602"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.phrs.2019.03.020","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T11:51:12Z","timestamp":1553341872000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients"],"prefix":"10.1016","volume":"143","author":[{"given":"Ahmed","family":"AlTurki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarvinder","family":"Dhanjal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithwish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidal","family":"Essebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.phrs.2019.03.020_bib0005","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"41","key":"10.1016\/j.phrs.2019.03.020_bib0010","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"issue":"11 Suppl. 1","key":"10.1016\/j.phrs.2019.03.020_bib0015","first-page":"I3","article-title":"Epidemiology and stratification of risk for sudden cardiac death","volume":"28","author":"Podrid","year":"2005","journal-title":"Clin. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter\u2013defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.phrs.2019.03.020_bib0025","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.020_bib0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0035","first-page":"174","article-title":"Canadian Cardiovascular Society\/Canadian Heart Rhythm Society 2016 implantable cardioverter-defibrillator guidelines","volume":"33","author":"Bennett","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.020_bib0040","first-page":"1342","article-title":"2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0045","first-page":"270","article-title":"A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality","volume":"31","author":"Proietti","year":"2015","journal-title":"Can. J. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.020_bib0050","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.amjcard.2005.11.048","article-title":"Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?","volume":"97","author":"Germano","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131570","article-title":"ICD shock, not ventricular fibrillation, causes elevation of high sensitive troponin T after defibrillation threshold testing\u2013the prospective, randomized, multicentre tropshock-trial","volume":"10","author":"Semmler","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.hrthm.2010.02.026","article-title":"ICD shocks: not just the \"straw that broke the camel\u2019s back\"","volume":"7","author":"Tandri","year":"2010","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.RES.0000013403.24495.CC","article-title":"Optical mapping of arrhythmias induced by strong electrical shocks in myocyte cultures","volume":"90","author":"Fast","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.03.020_bib0070","article-title":"Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: a meta-analysis","author":"AlTurki","year":"2017","journal-title":"Hellenic J. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.020_bib0075","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1113\/JP270534","article-title":"Therapy for ventricular arrhythmias in structural heart disease: a multifaceted challenge","volume":"594","author":"Proietti","year":"2016","journal-title":"J. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0080","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pace.12827","article-title":"A historical perspective on the role of functional lines of block in the re-entrant circuit of ventricular tachycardia","volume":"39","author":"Proietti","year":"2016","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.joa.2014.04.003","article-title":"Molecular mechanisms of heart failure progression associated with implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias","volume":"30","author":"Tsuji","year":"2014","journal-title":"J. Arrhythm."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.03.020_bib0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eupc.2005.04.011","article-title":"Electroporation of the heart","volume":"7","author":"Nikolski","year":"2005","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0095","first-page":"85","article-title":"Current concepts on ventricular fibrillation: a vicious circle of cardiomyocyte calcium overload in the initiation, maintenance, and termination of ventricular fibrillation","volume":"4","author":"Zaugg","year":"2004","journal-title":"Indian Pacing Electrophysiol. J."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.hrthm.2011.11.035","article-title":"Point: implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias increase mortality","volume":"9","author":"Sweeney","year":"2012","journal-title":"Heart Rhythm"},{"issue":"10","key":"10.1016\/j.phrs.2019.03.020_bib0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamainternmed.2013.428","article-title":"Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches","volume":"173","author":"Borne","year":"2013","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15420\/AER.2016.10.2","article-title":"Antiarrhythmic drug therapy to avoid implantable cardioverter defibrillator shocks","volume":"5","author":"Abboud","year":"2016","journal-title":"Arrhythm. Electrophysiol. Rev."},{"issue":"13","key":"10.1016\/j.phrs.2019.03.020_bib0115","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.phrs.2019.03.020_bib0125","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1161\/CIRCULATIONAHA.114.011283","volume":"130","author":"Ruwald","year":"2014","journal-title":"Circulation."},{"issue":"9169","key":"10.1016\/j.phrs.2019.03.020_bib0130","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0135","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.020_bib0140","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.amjcard.2018.01.011","article-title":"Meta-analysis comparing neurohumoral antagonist use in patients >\/=75 years versus <75 years receiving cardiac resynchronization therapy","volume":"121","author":"AlTurki","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0145","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1345\/aph.1M140","article-title":"Use of beta-blockers in patients with an implantable cardioverter defibrillator","volume":"43","author":"LaPointe","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"Suppl. A","key":"10.1016\/j.phrs.2019.03.020_bib0150","article-title":"Safety and tolerability of beta-blockers: prejudices and reality","volume":"11","author":"Erdmann","year":"2009","journal-title":"Eur. Heart J. Suppl."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0155","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","article-title":"Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient information","volume":"168","author":"Barron","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0160","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2011.01.006","article-title":"Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology\u2019s NCDR((R))","volume":"161","author":"Kontos","year":"2011","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(99)00234-X","article-title":"Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial","volume":"34","author":"Exner","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0170","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.amjcard.2005.04.046","article-title":"Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II)","volume":"96","author":"Brodine","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/B:HREV.0000046369.90417.db","article-title":"Beta blockers as anti-arrhythmic agents","volume":"9","author":"Anh","year":"2004","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.phrs.2019.03.020_bib0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2261-13-52","article-title":"Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc. Disord."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0185","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0735-1097(00)00659-8","article-title":"Beta-blockers and ventricular arrhythmias in dilated cardiomyopathy","volume":"35","author":"Fauchier","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.phrs.2019.03.020_bib0190","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2018.02.056","article-title":"Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator","volume":"71","author":"Chatzidou","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.phrs.2019.03.020_bib0195","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jacc.2013.01.020","article-title":"Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)","volume":"61","author":"Ruwald","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0200","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0735-1097(86)80268-6","article-title":"Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics","volume":"7","author":"Kato","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0205","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0002-8703(99)70484-9","article-title":"Sotalol: an important new antiarrhythmic","volume":"137","author":"Anderson","year":"1999","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1751-7133.2009.00062.x","article-title":"Sotalol as adjunctive therapy to implantable cardioverter-defibrillators in heart failure patients","volume":"15","author":"Chaki","year":"2009","journal-title":"Congest. Heart Fail."},{"issue":"9019","key":"10.1016\/j.phrs.2019.03.020_bib0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.phrs.2019.03.020_bib0220","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of implantable-defibrillator shocks by treatment with sotalol","volume":"340","author":"Pacifico","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0735-1097(98)00521-X","article-title":"Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment","volume":"33","author":"Kuhlkamp","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of \u03b2-blockers, amiodarone plus \u03b2-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the optic study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0235","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.hrthm.2011.08.005","article-title":"The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients","volume":"9","author":"Fischer","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.phrs.2019.03.020_bib0240","first-page":"465","article-title":"Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia","volume":"6","author":"Van Herendael","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(97)00114-4","article-title":"Cellular electropharmacology of amiodarone","volume":"35","author":"Kodama","year":"1997","journal-title":"Cardiovasc. Res."},{"issue":"4 Pt 2","key":"10.1016\/j.phrs.2019.03.020_bib0250","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","article-title":"Amiodarone pharmacokinetics","volume":"106","author":"Holt","year":"1983","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00562807","article-title":"Pharmacokinetics of amiodarone after intravenous and oral administration","volume":"19","author":"Andreasen","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"693","key":"10.1016\/j.phrs.2019.03.020_bib0260","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/pgmj.59.693.440","article-title":"Renal elimination of amiodarone and its desethyl metabolite","volume":"59","author":"Harris","year":"1983","journal-title":"Postgrad. Med. J."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0265","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/01.CIR.88.3.1063","article-title":"Frequency-dependent electrophysiologic effects of amiodarone in humans","volume":"88","author":"Sager","year":"1993","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0270","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/europace\/euq073","article-title":"Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators","volume":"12","author":"Van Herendael","year":"2010","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.phrs.2019.03.020_bib0275","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.96.9.2823","article-title":"Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death","volume":"96","author":"Sim","year":"1997","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.phrs.2019.03.020_bib0280","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1161\/01.CIR.99.17.2268","article-title":"Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators","volume":"99","author":"Boutitie","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.CIR.67.1.45","article-title":"Side effects of long-term amiodarone therapy","volume":"67","author":"Harris","year":"1983","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.phrs.2019.03.020_bib0290","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0002-9149(83)90515-5","article-title":"Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation","volume":"52","author":"Morady","year":"1983","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0295","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/clc.4960130509","article-title":"Mexiletine: pharmacology and therapeutic use","volume":"13","author":"Manolis","year":"1990","journal-title":"Clin. Cardiol."},{"issue":"5 Pt 2","key":"10.1016\/j.phrs.2019.03.020_bib0300","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0002-8703(84)90177-7","article-title":"Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques","volume":"107","author":"Schoenfeld","year":"1984","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40119-013-0012-5","article-title":"Current and emerging antiarrhythmic drug therapy for ventricular tachycardia","volume":"2","author":"Williams","year":"2013","journal-title":"Cardiol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0315","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0002-9149(83)90365-X","article-title":"Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients","volume":"51","author":"Waspe","year":"1983","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0320","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/jce.13431","article-title":"Mexiletine or catheter ablation after amiodarone failure in the VANISH trial","volume":"29","author":"Deyell","year":"2018","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"9247","key":"10.1016\/j.phrs.2019.03.020_bib0325","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(00)03402-4","article-title":"Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial","volume":"356","author":"Kober","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.020_bib0330","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction","volume":"341","author":"Torp-Pedersen","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0335","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1540-8167.2011.02183.x","article-title":"Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies","volume":"23","author":"Baquero","year":"2012","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"23","key":"10.1016\/j.phrs.2019.03.020_bib0340","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/euhj.2001.2679","article-title":"A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease","volume":"22","author":"Boriani","year":"2001","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0345","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2010.07.047","article-title":"Efficacy and safety of dofetilide in the treatment of frequent ventricular tachyarrhythmias after amiodarone intolerance or failure","volume":"57","author":"Pinter","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.phrs.2019.03.020_bib0350","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1161\/01.CIR.0000149240.98971.A8","article-title":"Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator","volume":"110","author":"Dorian","year":"2004","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.phrs.2019.03.020_bib0355","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.CIR.0000117090.01718.2A","article-title":"Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification","volume":"109","author":"Camm","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.03.020_bib0360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2016.10.025","article-title":"Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: the SHIELD-2 trial","volume":"185","author":"Robinson","year":"2017","journal-title":"Am. Heart J."},{"issue":"13","key":"10.1016\/j.phrs.2019.03.020_bib0365","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1517\/14656566.8.13.2149","article-title":"Ranolazine in patients with coronary artery disease","volume":"8","author":"Scirica","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0370","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/joa3.12031","article-title":"Impact of ranolazine on ventricular arrhythmias \u2013 a systematic review","volume":"34","author":"Bazoukis","year":"2018","journal-title":"J. Arrhythm."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.020_bib0375","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.bjp.0705879","article-title":"Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects","volume":"142","author":"Schram","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.phrs.2019.03.020_bib0380","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.020_bib0385","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/j.1540-8159.2011.03208.x","article-title":"Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks","volume":"34","author":"Bunch","year":"2011","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0390","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2018.04.086","article-title":"Ranolazine in high-risk patients with implanted cardioverter-defibrillators: the RAID trial","volume":"72","author":"Zareba","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0395","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCULATIONAHA.106.618421","article-title":"Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial","volume":"114","author":"Hohnloser","year":"2006","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.phrs.2019.03.020_bib0400","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1540-8167.1996.tb00469.x","article-title":"d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy","volume":"7","author":"Dorian","year":"1996","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.phrs.2019.03.020_bib0405","doi-asserted-by":"crossref","first-page":"i1855","DOI":"10.1136\/bmj.i1855","article-title":"Effect of age and sex on efficacy and tolerability of \u03b2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis","volume":"353","author":"Kotecha","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0410","volume":"20","author":"Group","year":"2018","journal-title":"EP Europace"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0415","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9149(02)03378-7","article-title":"Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues","volume":"91","author":"Wolbrette","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0420","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.020_bib0425","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0735-1097(02)02709-2","article-title":"Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction","volume":"41","author":"Essebag","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.phrs.2019.03.020_bib0430","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1001\/archinte.167.15.1648","article-title":"Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation","volume":"167","author":"Essebag","year":"2007","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0435","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0440","first-page":"1328","article-title":"ACC\/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)","volume":"28","author":"Ryan","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0445","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-8703(99)70401-1","article-title":"Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction","volume":"137","author":"Sadowski","year":"1999","journal-title":"Am. Heart J."},{"issue":"13","key":"10.1016\/j.phrs.2019.03.020_bib0450","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/jama.1988.03410130118036","article-title":"Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials","volume":"260","author":"MacMahon","year":"1988","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.020_bib0455","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1001\/archinte.1989.00390120056011","article-title":"Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction","volume":"149","author":"Hine","year":"1989","journal-title":"Arch. Intern. Med."},{"issue":"13","key":"10.1016\/j.phrs.2019.03.020_bib0460","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.1993.03510130095038","article-title":"Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials","volume":"270","author":"Teo","year":"1993","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.phrs.2019.03.020_bib0465","first-page":"1150","article-title":"Electrical storm: incidence, prognosis and therapy","volume":"8","author":"Sagone","year":"2015","journal-title":"J. Atr. Fibrillation"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0470","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4330\/wjc.v9.i6.521","article-title":"Management of ventricular tachycardia storm in patients with structural heart disease","volume":"9","author":"Muser","year":"2017","journal-title":"World J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0475","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0735-1097(95)00427-0","article-title":"Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group","volume":"27","author":"Levine","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.020_bib0480","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1161\/01.CIR.92.11.3264","article-title":"Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group","volume":"92","author":"Scheinman","year":"1995","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.020_bib0485","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/01.CIR.96.6.1914","article-title":"Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death","volume":"96","author":"Billman","year":"1997","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0490","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.CIR.102.7.742","article-title":"Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy","volume":"102","author":"Nademanee","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0495","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/HCO.0000000000000242","article-title":"Recent advances in ablation of ventricular tachycardia associated with structural heart disease: overcoming the challenges of functional and fixed barriers","volume":"31","author":"Proietti","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0500","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/europace\/euu326","article-title":"Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome","volume":"17","author":"Proietti","year":"2015","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0505","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11517-008-0428-6","article-title":"Guidance for catheter ablation of ventricular arrhythmia","volume":"47","author":"Potse","year":"2009","journal-title":"Med. Biol. Eng. Comput."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.020_bib0510","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005663","article-title":"Effect of baseline antiarrhythmic drug on outcomes with ablation in ischemic ventricular tachycardia: a VANISH substudy (ventricular tachycardia ablation versus escalated antiarrhythmic drug therapy in ischemic heart disease)","volume":"11","author":"Parkash","year":"2018","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.020_bib0515","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/jce.13419","article-title":"Quality of life with ablation or medical therapy for ventricular arrhythmias: a substudy of VANISH","volume":"29","author":"Gula","year":"2018","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.020_bib0520","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jacep.2018.01.007","article-title":"Cost effectiveness of ventricular tachycardia ablation versus escalation of antiarrhythmic drug therapy: the VANISH trial","volume":"4","author":"Coyle","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.020_bib0525","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacep.2018.03.013","article-title":"Prognostic value of noninducibility on outcomes of ventricular tachycardia ablation: a VANISH substudy","volume":"4","author":"Essebag","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.020_bib0530","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.phrs.2019.03.020_bib0535","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9146","key":"10.1016\/j.phrs.2019.03.020_bib0540","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"9053","key":"10.1016\/j.phrs.2019.03.020_bib0545","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"issue":"9053","key":"10.1016\/j.phrs.2019.03.020_bib0550","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:59:15Z","timestamp":1760911155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819302580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":110,"alternative-id":["S1043661819302580"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.020","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}